Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Common Equity (2020 - 2025)

Ovid Therapeutics' Common Equity history spans 6 years, with the latest figure at $130.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 91.51% year-over-year to $130.7 million; the TTM value through Dec 2025 reached $130.7 million, up 91.51%, while the annual FY2025 figure was $130.7 million, 91.51% up from the prior year.
  • Common Equity reached $130.7 million in Q4 2025 per OVID's latest filing, up from $44.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $221.1 million in Q1 2021 to a low of $44.7 million in Q3 2025.
  • Average Common Equity over 5 years is $120.9 million, with a median of $115.8 million recorded in 2023.
  • Peak YoY movement for Common Equity: soared 578.12% in 2021, then tumbled 41.41% in 2025.
  • A 5-year view of Common Equity shows it stood at $179.7 million in 2021, then fell by 26.41% to $132.3 million in 2022, then plummeted by 33.62% to $87.8 million in 2023, then fell by 22.29% to $68.2 million in 2024, then soared by 91.51% to $130.7 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Common Equity are $130.7 million (Q4 2025), $44.7 million (Q3 2025), and $55.8 million (Q2 2025).